Ocena przydatności diagnostycznej i prognostycznej N-acetyloglukozaminy transferazy z wiązaniem O-glikozydowym w przebiegu transformacji nowotworowej pęcherza moczowego u kobiet w wieku pomenopauzalnym

Cel pracy: Celem przeprowadzonych badań była ocena przydatności oznaczania ekspresji genu N-acetyloglukozaminytransferazy z wiązaniem O-glikozydowym (O-linked N-acetylglucosamine transferase – OGT) w diagnozowaniunowotworów pęcherza moczowego u kobiet w wieku pomenopauzalnym oraz w prognozowaniuprzebiegu transformacji nowotworowej tego narządu. Materiał i metody: Materiał użyty do badań stanowił mocz pozyskany od 52 chorych ze zdiagnozowanyminowotworami pęcherza moczowego. W preparatach tych oznaczono ekspresję OGT na poziomie matrycowegokwasu rybonukleinowego (mRNA) w czasie rzeczywistym (real-time) metodą reakcji łańcuchowej polimerazy(polimerase chain reaction – PCR). Materiał kontrolny stanowił mocz pozyskany od 37 kobiet, u których w badaniuultrasonograficznym (USG) nie stwierdzono zmian nowotworowych. Wyznaczono wartość progową dlabadanego genu oraz obliczono czułość i swoistość tego markera. Wyniki: Przy progowej wartości OGT wynoszącej 416,93 czułość testu wynosiła 100%, a swoistość 88,9%.Ekspresję OGT stwierdzono w 36 z 46 (78,2%) preparatów moczu pobranego od kobiet ze zdiagnozowanymrakiem pęcherza moczowego oraz w 18 z 37 (48,6%) preparatów moczu prawidłowego. Natomiast uwzględniającwartość progową, ekspresję OGT stwierdzono odpowiednio w 19 z 46 i w 1 z 37 analizowanych preparatów.Ekspresji OGT nie stwierdzono w moczu kobiet chorych ze zdiagnozowanym brodawczakowatym nowotworemprzejściowonabłonkowym o niskim potencjale złośliwości (papillary urothelial neoplasm of low malignant potential– PUNLMP). Wnioski: Oznaczanie ekspresji OGT na poziomie mRNA w moczu kobiet w wieku pomenopauzalnym, chorychna nowotwory pęcherza moczowego wydaje się użytecznym wskaźnikiem diagnostycznym i prognostycznymw przebiegu choroby

Ocena przydatności β-N-acetylo-D-glukozaminidazy i endogliny jako markerów molekularnych w diagnostyce nowotworów pęcherza moczowego u kobiet w wieku pomenopauzalnym

The aim of the study was to evaluate the usefulness of mRNA expression of b-N-acetyl-D-glucosaminidase (MGEA5) and endoglin (CD105) for bladder cancer diagnosis and disease prognosis in postmenopausal women.Material and methods: Expression of MGEA5 and CD105 in mRNA with PCR real-time method was estimated in a urine specimen from 30 women with diagnosed bladder cancer. The control group consisted of 20 women with negative cancer history and no changes in the urine specimen and ultrasound examination of the bladder. For both estimated genes, cut-off, specificity and sensitivity were estimated.Results and conclusions: At a cut-off value of MGEA5 of 98.3 sensitivity was 85.2% and specificity 95%. Expression of MGEA5 was established in 27 of 30 (90%) urine specimens taken from women with bladder cancer and in 100% (20 of 20) urine specimens from healthy women. Expression of CD105 was characterized by 100% sensitivity and 80% specificity. Cut-off was over 2.0. There was no CD105 expression in women with papillary urothelial neoplasms of low malignant potential (PUNLMP), in contrast to MGEA5 expression. Estimation of expression of both MGEA5 and CD105 in mRNA of urine specimens of postmenopausal women with urinary bladder may be a useful marker of diagnosis and prognosis of bladder carcinoma

Kamica pęcherza moczowego jako późne powikłanie leczenia wysiłkowego nietrzymania moczu u kobiet metodami małoinwazyjnymi

Introduction: The only effective way of treatment of Stress Urinary Incontinence (SUI) is operating treatment.New operating methods are less invasive but also have complications. One of observed complications is a shift ofthe tape or the thread to the urinary bladder with urinary stone formation. There is a variety of treatment methods:use of optical lithotripters, ultrasound and pneumatic probes and recently – a holmium laser. Aim of study: The aim of the study was to estimate the possibility of using a holmium: YAG laser (Omni puls– MAX™ holmium laser) in treating bladder stone disease after SUI operating procedures. Material and methods: From January 2009 to February 2010 in the Second Clinic of Urology of the MedicalUniversity of Lodz there were treated six women with urinary bladder stones after SUI operating procedureswhere the thread or tape moved into the urinary bladder. The stone diameter ranged from 1.6 cm to 3.5 cm.Lithotripsy was done using 80 W holmium: YAG laser (omni puls MAX holmium laser) as an endoscopic procedure.The length of beam: 2100 nm. Energy used was 0.2-3.5 J. Results: In all cases, a urinary bladder stone was disintegrated and vacuumed, then with the same fibre thethread or tape was cut off from the bladder. After two days all patients were discharged from the hospital in goodgeneral condition. Conclusions: The holmium laser is a very effective way of treatment for patients with bladder stone diseasecomplications after SUI operating procedures, when the thread or tape is shifted to the bladder. The procedureis easy to perform and safe for the patient

Preliminary outcomes of the European multicentre experience with the ZSI 375 artificial urinary sphincter for treatment of stress urinary incontinence in men

Introduction The ZSI 375 is a new artificial urinary sphincter utilised in men suffering from stress urinary incontinence (SUI). We present the first European multicentre study on the effectiveness of ZSI 375. Material and methods This study was conducted in a retrospective, non-randomized format in centres across Europe. Between May 2009 and December 2014, ZSI 375 was fitted in 109 SUI patients following radical prostatectomy, transurethral resection of prostate (TURP), rectal surgery and high intensity focused ultrasound (HIFU). Patients with history of pelvic radiotherapy or previous surgical treatment for incontinence or stricture were excluded from the series. Follow-up was completed by December 2016. The key outcome measures included overall improvement and complication rates. Results A total of 109 patients in 10 European centres were recruited and had the ZSI 375 device implanted. The average patient age was 72 years old. The indication for the majority of patients was incontinence following radical prostatectomy (100/109 patients, 91.74%). On average, patients were incontinent for 48.6 months prior to treatment. All patients used ≥4 pads daily at baseline and thus were classified as suffering from ‘severe incontinence’. The average follow-up until the final visit was 43 months. The pad usage decreased to 0.84 on average by the last visit. There were no reported cases of device infection. A total of 9 patients had urethral cuff erosion (8.25%),which was the most common complication in this series. A further 3 men (2.75%) experienced mechanical failure requiring subsequent device reimplantation. The implantation of the ZSI 375 device was considered successful in 92.66% of patients. Conclusions The ZSI 375 is an effective surgical treatment option in men with severe stress urinary incontinence. © 2019, Polish Urological Association. All rights reserved